Effect of Oral L-Carnitine on Inflammatory and Nutritional Factors in Hemodialysis Patients
Status:
COMPLETED
Trial end date:
2021-03-08
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate whether oral L-carnitine supplementation helps reduce inflammation and improve nutritional status in patients with end-stage kidney disease who are undergoing long-term hemodialysis.
A total of 50 participants will be randomly assigned to receive either:
* Oral L-carnitine solution (1 g, three times per week after dialysis), or
* A placebo solution that looks and tastes the same but does not contain L-carnitine.
The study will last for three months. Researchers will assess changes in:
* Inflammatory markers (high-sensitivity C-reactive protein, hs-CRP)
* Nutritional markers (serum albumin, ferritin)
* Blood lipid profile (cholesterol, LDL, HDL, triglycerides)
The findings from this study are expected to provide insights into the potential clinical benefits of oral L-carnitine supplementation in maintenance hemodialysis patients.